An Insider Scott Mendel Sold 218 shares of GenMark Diagnostics, Inc. (GNMK); 8 Analysts Covering Webster Financial (WBS)

Webster Financial Corporation (NYSE:WBS) Logo

Among 19 analysts covering Webster Financial (NYSE:WBS), 8 have Buy rating, 1 Sell and 10 Hold. Therefore 42% are positive. Webster Financial had 60 analyst reports since July 20, 2015 according to SRatingsIntel. On Tuesday, January 23 the stock rating was maintained by Sandler O’Neill with “Hold”. The rating was upgraded by Zacks on Tuesday, September 22 to “Buy”. RBC Capital Markets maintained the shares of WBS in report on Friday, January 22 with “Sector Perform” rating. The stock of Webster Financial Corporation (NYSE:WBS) earned “Buy” rating by Guggenheim on Friday, January 15. The firm has “Market Perform” rating by Wells Fargo given on Monday, November 14. Barclays Capital downgraded the shares of WBS in report on Friday, August 5 to “Equal-Weight” rating. The firm has “Hold” rating by Piper Jaffray given on Monday, April 23. The firm has “Hold” rating given on Tuesday, September 8 by Zacks. The stock has “Hold” rating by Jefferies on Friday, June 9. The stock of Webster Financial Corporation (NYSE:WBS) earned “Buy” rating by Keefe Bruyette & Woods on Monday, February 26. See Webster Financial Corporation (NYSE:WBS) latest ratings:

04/05/2018 Broker: Deutsche Bank Old Rating: Hold New Rating: Hold Old Target: $61 New Target: $64 Maintain
24/04/2018 Broker: Morgan Stanley Old Rating: Underweight New Rating: Underweight Old Target: $56 New Target: $59 Maintain
23/04/2018 Broker: Piper Jaffray Rating: Hold New Target: $60.0000 Maintain
20/04/2018 Broker: Boenning & Scattergood Rating: Hold Maintain
19/04/2018 Broker: Jefferies Rating: Hold New Target: $63.0000 Maintain
22/03/2018 Broker: UBS Rating: Neutral New Target: $45 Initiates Coverage On
26/02/2018 Broker: Keefe Bruyette & Woods Rating: Buy New Target: $75.0 Maintain
26/01/2018 Broker: Morgan Stanley Old Rating: Underweight New Rating: Underweight Old Target: $54 New Target: $56 Maintain
24/01/2018 Broker: Jefferies Rating: Hold New Target: $62.0 Maintain
24/01/2018 Broker: Boenning & Scattergood Rating: Hold Maintain

Webster Financial Corporation operates as the holding firm for Webster Bank, National Association that provides financial services to individuals, families, and businesses in the United States. The company has market cap of $5.67 billion. It operates through four divisions: Commercial Banking, Community Banking, HSA Bank, and Private Banking. It has a 23.06 P/E ratio. The Commercial Banking segment provides lending, deposit, and cash management services to middle market companies; and asset lending, commercial real estate, and equipment finance, as well as treasury and payment services, which include government and institutional banking.

More notable recent Webster Financial Corporation (NYSE:WBS) news were published by: Bizjournals.com which released: “Santander gets good news on regulatory, customer service marks” on May 01, 2018, also Seekingalpha.com with their article: “Buy the dip in banks – Morgan Stanley” published on April 30, 2018, Seekingalpha.com published: “Goldman Sachs, Kinder Morgan among those seen raising dividends next week” on April 13, 2018. More interesting news about Webster Financial Corporation (NYSE:WBS) were released by: Prnewswire.com and their article: “Webster Financial Corporation Increases Common Dividend” published on April 23, 2018 as well as Seekingalpha.com‘s news article titled: “Ethan Allen, Legg Mason among S&P 1500 stocks seen hiking payouts” with publication date: April 20, 2018.

The stock increased 1.84% or $1.11 during the last trading session, reaching $61.58. About 576,936 shares traded or 2.87% up from the average. Webster Financial Corporation (NYSE:WBS) has risen 10.54% since May 5, 2017 and is uptrending. It has underperformed by 1.01% the S&P500.

Since January 25, 2018, it had 0 insider purchases, and 8 insider sales for $5.61 million activity. MORRIS DAWN C sold $147,100 worth of Webster Financial Corporation (NYSE:WBS) on Monday, April 23. The insider BECKER JOEL S sold 7,473 shares worth $455,853. 7,400 Webster Financial Corporation (NYSE:WBS) shares with value of $448,514 were sold by MORSE LAURENCE C. The insider SMITH JAMES COPENHAVER sold $3.63 million. BLEY DANIEL had sold 4,900 shares worth $293,706. Pettie Mark had sold 3,291 shares worth $185,415 on Thursday, February 1.

Investors sentiment increased to 1.16 in 2017 Q4. Its up 0.20, from 0.96 in 2017Q3. It improved, as 18 investors sold Webster Financial Corporation shares while 75 reduced holdings. 26 funds opened positions while 82 raised stakes. 85.11 million shares or 0.62% more from 84.59 million shares in 2017Q3 were reported. Grandeur Peak Limited stated it has 0.09% of its portfolio in Webster Financial Corporation (NYSE:WBS). Blackrock holds 0.02% of its portfolio in Webster Financial Corporation (NYSE:WBS) for 8.13 million shares. 16,639 were reported by Sg Americas Securities. Gemmer Asset Limited Liability accumulated 0.01% or 307 shares. Mark Sheptoff Planning Llc holds 0.3% or 8,229 shares. 404,579 are owned by Hood River Capital Ltd Liability. Thrivent Finance For Lutherans stated it has 20,043 shares. Brinker Cap holds 21,522 shares or 0.05% of its portfolio. Fisher Asset Llc reported 0.13% stake. Brown Advisory stated it has 0.17% in Webster Financial Corporation (NYSE:WBS). 883 are owned by Hanseatic Mngmt Svcs. 45,362 are owned by Mason Street Ltd Liability Corp. Federated Invsts Inc Pa owns 37,610 shares for 0.01% of their portfolio. Moreover, Rmb Lc has 0.3% invested in Webster Financial Corporation (NYSE:WBS) for 202,439 shares. Ftb Advisors invested in 0% or 415 shares.

Since January 23, 2018, it had 1 buying transaction, and 26 selling transactions for $311,956 activity. Another trade for 848 shares valued at $4,350 was made by McNally James B. on Friday, February 2. Kayyem Jon Faiz also sold $759 worth of GenMark Diagnostics, Inc. (NASDAQ:GNMK) on Friday, February 2. 1,052 GenMark Diagnostics, Inc. (NASDAQ:GNMK) shares with value of $4,387 were sold by Mitchell Brian Andrew. On Tuesday, February 20 MASSARANY HANY sold $28,772 worth of GenMark Diagnostics, Inc. (NASDAQ:GNMK) or 6,584 shares. Stier Eric sold $54,600 worth of stock or 10,000 shares. Shares for $19,662 were sold by Gleeson Michael. 6,275 GenMark Diagnostics, Inc. (NASDAQ:GNMK) shares with value of $26,167 were sold by Mendel Scott.

GenMark Diagnostics, Inc., a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. The company has market cap of $391.77 million. The firm provides XT-8 instrument, and related diagnostic and research tests, as well as certain custom manufactured reagents that enable reference laboratories and hospitals to support a range of molecular tests with a workstation and disposable test cartridges. It currently has negative earnings. It offers diagnostic tests for use with its XT-8 system that includes respiratory viral panel, cystic fibrosis genotyping test, warfarin sensitivity test, and thrombophilia risk test, as well as HCV genotyping test and associated custom manufactured reagents, and 2C19 genotyping test.

Among 6 analysts covering Genmark Diagnostics (NASDAQ:GNMK), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Genmark Diagnostics has $1700 highest and $8 lowest target. $11.20’s average target is 58.42% above currents $7.07 stock price. Genmark Diagnostics had 21 analyst reports since October 14, 2015 according to SRatingsIntel. The firm has “Buy” rating by Needham given on Wednesday, August 30. The stock of GenMark Diagnostics, Inc. (NASDAQ:GNMK) has “Buy” rating given on Friday, January 19 by Needham. The stock of GenMark Diagnostics, Inc. (NASDAQ:GNMK) earned “Buy” rating by Needham on Wednesday, February 24. The firm has “Buy” rating by Needham given on Wednesday, May 2. The firm has “Buy” rating given on Monday, October 30 by Canaccord Genuity. The stock of GenMark Diagnostics, Inc. (NASDAQ:GNMK) has “Buy” rating given on Monday, June 12 by Needham. The company was downgraded on Friday, November 3 by Raymond James. The stock of GenMark Diagnostics, Inc. (NASDAQ:GNMK) has “Buy” rating given on Friday, November 3 by Canaccord Genuity. The firm has “Buy” rating given on Monday, August 7 by Canaccord Genuity. The rating was maintained by Needham with “Buy” on Tuesday, January 24.

Investors sentiment decreased to 1.26 in 2017 Q4. Its down 0.62, from 1.88 in 2017Q3. It worsened, as 14 investors sold GenMark Diagnostics, Inc. shares while 21 reduced holdings. 18 funds opened positions while 26 raised stakes. 53.33 million shares or 5.73% less from 56.57 million shares in 2017Q3 were reported. Citigroup Inc stated it has 0% in GenMark Diagnostics, Inc. (NASDAQ:GNMK). Millennium Mngmt Lc, a New York-based fund reported 604,087 shares. Whittier reported 196 shares. Old Natl State Bank In has invested 0.01% of its portfolio in GenMark Diagnostics, Inc. (NASDAQ:GNMK). Raymond James Associates stated it has 13,250 shares. Blair William And Il accumulated 93,266 shares. Sg Americas Secs Limited Liability Corporation invested in 0% or 10,400 shares. Bancorporation Of America De stated it has 864,208 shares or 0% of all its holdings. Cadian Capital Management L P invested in 5.02M shares. Vanguard Grp Inc holds 0% or 2.44 million shares in its portfolio. Moreover, Tci Wealth Advisors Inc has 0.01% invested in GenMark Diagnostics, Inc. (NASDAQ:GNMK) for 6,811 shares. State Street owns 906,076 shares. Teacher Retirement Of Texas invested in 0% or 17,628 shares. State Common Retirement Fund stated it has 0% of its portfolio in GenMark Diagnostics, Inc. (NASDAQ:GNMK). Barclays Public Ltd Co has 0% invested in GenMark Diagnostics, Inc. (NASDAQ:GNMK).

More important recent GenMark Diagnostics, Inc. (NASDAQ:GNMK) news were published by: Globenewswire.com which released: “GenMark Diagnostics Reports First Quarter 2018 Results” on May 01, 2018, also Globenewswire.com published article titled: “GenMark Diagnostics Schedules First Quarter Financial Results Conference Call for May 1, 2018”, Nasdaq.com published: “GenMark Diagnostics to Present at the Bank of America Merrill Lynch 2018 Health Care Conference” on April 25, 2018. More interesting news about GenMark Diagnostics, Inc. (NASDAQ:GNMK) was released by: Streetinsider.com and their article: “After-Hours Stock Movers 05/01: (CRAY) (CYH) (AAPL) Higher; (SNAP) (YUMC) (GILD) Lower (more..)” with publication date: May 01, 2018.

Webster Financial Corporation (NYSE:WBS) Institutional Positions Chart